Referenser Stroke och TIA

Sekundärprofylax efter stroke/TIA

  • Adam et al, Ann Intern Med 2012 Aug 28: Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
  • Benavente et al, N Engl J Med. 2012;367:817–825: Effects of clopidogrel added to aspirin in patients with recent lacunar stroke
  • Boulouis et al, J Neurol Neurosurg Psychiatry. 2017 Oct 13.: jnnp-2017-316631. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
  • Camm et al, Eur Heart J. 2012 Aug 24, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
  • Connolly et al, N Engl J Med 2009 Sep 17;361(12):1139-51, Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY trial).
  • Connolly et al, N Engl J Med. 2011 Mar 3;364(9):806-17. Apixaban in patients with atrial fibrillation. (AVERROES)
  • Connolly et al, N Engl J Med. 2019 Apr 4;380(14):1326-1335. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. (ANNEXA-4)
  • CURRENT– OASIS 7 Investigators, N Engl J Med 2010;363:930-42. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
  • Diener et al, J Neurol Sci 1996;143:1-13, Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke (ESPS2)
  • Diener et al, Lancet, 364 (2004), pp. 331–337, Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients randomized, double-blind, placebo-controlled trial (MATCH)
  • Diener et al, N Engl J Med. 2019 May 16;380(20):1906-1917. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. (RE-SPECT ESUS)
  • Diener et al, Lancet Neurol 2010; 9: 1157–63, Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
  • Halkes et al, ESPRIT Study Group, Lancet 2006;367:1665–1673, Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin: a randomised controlled trial (ESPRIT).
  • Friberg et al, Open Heart 2017;4:e000682. doi:10.1136/openhrt-2017-000682 Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
  • Gorelick et al, Stroke Research and Treatment, Volume 2013, Article ID 727842 Review Article: Advances in Our Understanding of ‘‘Resistance’’ to Antiplatelet Agents for Prevention of Ischemic Stroke
  • Granger at al, N Engl J Med 2011 Sep 15;365(11):981-92, Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE trial)
  • Guigliano et al, N Engl J Med 2013 Nov 28;369(22):2093-104, Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48 trial)
  • Halvorsen et al, Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
  • Hart et al, N Engl J Med. 2018 Jun 7;378(23):2191-2201, Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source (NAVI- GATE-ESUS trial)
  • Huang at al, JAMA Neurol. 2018 Dec 1;75(12):1511-1518. Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
  • Huhtakangas et al, Int J Stroke. 2015 Aug;10(6):876-81, Improved survival of patients with warfarin - associated intracerebral haemorrhage: a retrospective longitudinal population-based study
  • Johnston et al, N Engl J Med. 2016 Jul 7;375(1):35-43, Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack (SOCRATES trial)
  • Johnston et al, N Engl J Med. 2018 Jul 19;379(3):215-225, Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA (POINT trial)
  • Kermer et al, Int J Stroke. 2017 Jun;12(4):383-391, Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
  • Kim et al, Stroke 2019 Dec;50(12):3503-3511, Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis,
  • Lee et al, Stroke 2017;48:2610–2613, Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin, A Systematic Review and Meta-Analysis
  • Liu et al, Cardiovascular Drugs and Therapy volume 34, pages 569-578(2020) (link.springer.com)
  • Antikoagulantiabehandling vid förmaksflimmer - behandlingsrekommendation, Läkemedelsverket (lakemedelsverket.se)
  • Ntaois et al, Stroke. 2017;48:2494-2503, Real-World Setting Comparison of Nonvitamin-K Antagonist
  • Olesen et al, Thrombosis and Hemostasis 2011: 106: 739-749, Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ’real world’ nationwide cohort study.
  • Parry-Jones et al, Ann Neurol. 2015 Jul;78(1):54-62, Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage.
  • Patel et al, N Engl J Med 2011;365:883-91, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF trial)
  • Pink et al, BMJ 2011, Oct 31; 343, Dabigatran etexilate versus warfarin in management of non-valvular at-rial fibrillation in UK context: quantitative benefit-harm and economic analyses
  • Pollack et al, N Engl J Med. 2017 Aug 3;377(5):431-441, Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. (RE-VERSE AD)
  • Reddy et al, J Am Coll Cardiol. 2017 Nov 4. pii: S0735-1097(17)41187-9, 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
  • Rothwell et al, Lancet. 2007 Oct 20;370(9596):1432-42, Effect of urgent treatment of transient ischaemic attack and minor stroke on early recur- rent stroke (EXPRESS study): a prospective population-based sequential comparison.
  • Sacco et al, N Engl J Med 2008 Sep 18;359(12):1238-51. Epub 2008 Aug 27, Aspirin and extended-release dipy-ridamole versus clopidogrel for recurrent stroke (PROFESS trial).
  • Saxena et al, The Cochrane Library 2008, Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack
  • Schulz, Maturitas. 2013 Nov;76(3):267-71. Drug treatments in the secondary prevention of ischaemic stroke.
  • Siegal et al, N Engl J Med. 2015 Dec 17;373(25):2413-24. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
  • Sjalander et al, Thromb Res. 2018 Jul;167:113-118. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
  • Socialstyrelsen, Nationella riktlinjer for vård vid stroke 2018 Nationella riktlinjer för vård vid stroke - Socialstyrelsen
  • Staerk et al, J Intern Med. 2018 Jan;283(1):45-55. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
  • Steiner et al, Lancet Neurol. 2016 May;15(6):566-73. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.
  • Wallentin et al, Lancet 2010: 376: 975-83: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
  • Wang et al, N Engl J Med 2013;369:11-19. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE)
  • Webb, A.J., et al., Lancet, 2010. 375(9718): p. 906-15. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.
  • Wright et al, N Engl J Med. 2015 Nov 26;373(22):2103-16. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Fick du hjälp av informationen på sidan?

Tänk på att

Informationen på webbplatsen är till för offentlig och privat vårdpersonal i Skåne.

Tack för din hjälp att förbättra webbplatsen, dina synpunkter har skickats till webbredaktionen.